DTIL - Precision BioSciences, Inc.

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

• 
  Conn's (CONN) Reports Q1 Loss, Lags Revenue Estimates

  Zacks
• 
  Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates

  Zacks

Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.

Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.

Horizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

Horizon's (HZNP) earnings and revenues lag estimates in the second quarter of 2022. The company lowers full-year revenue guidance for 2022. Shares were down in pre-market trading.

Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.

Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2

Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.

Is a Beat in Store for Alkermes (ALKS) This Earnings Season?

Alkermes' (ALKS) second-quarter 2022 results set to report earnings and revenues figures and provide updates on its portfolio of marketed drugs.

All You Need to Know About Precision BioSciences (DTIL) Rating Upgrade to Strong Buy

Precision BioSciences (DTIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal

The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.

Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.

Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA

The FDA's potential approval of Perrigo (PRGO) unit, HRA Pharma's OTC birth control pills can make the drug the first of its kind to be made available without prescription in the United States.

Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint

Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.

Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion

The FDA approves Horizon's (HZNP) sBLA for Krystexxa injection plus methotrexate to help people suffering from uncontrolled gout achieve a complete response to therapy.

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why

The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.

Adverum (ADVM) Completes IND Amendment for Gene Therapy Study

Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.

Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU

Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.

Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why

Seagen (SGEN) is riding on the strong uptake of its marketed drugs that are approved for different cancer indications. Further label expansion of these drugs should boost the top line.

Graybug (GRAY) to Review Strategic Alternatives, Stock Up

Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.

Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD

Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.

Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML

The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.

AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication

The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.